2 Intangible assets - Annual Report 2015 - DSM

2 Intangible assets

The carrying amount of intangible assets mainly comprises goodwill on the acquisition of NeoResins in 2005 (€358 million), Crina in 2006 (€9 million) and Pentapharm in 2007 (€36 million). For further information on these assets including the discussion of the related impairment tests please refer to note 8, 'Intangible assets' in the 'Consolidated financial statements'.